BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1431 related articles for article (PubMed ID: 27669025)

  • 21. Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum.
    Özcan A; Pausch P; Linden A; Wulf A; Schühle K; Heider J; Urlaub H; Heimerl T; Bange G; Randau L
    Nat Microbiol; 2019 Jan; 4(1):89-96. PubMed ID: 30397343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure Studies of the CRISPR-Csm Complex Reveal Mechanism of Co-transcriptional Interference.
    You L; Ma J; Wang J; Artamonova D; Wang M; Liu L; Xiang H; Severinov K; Zhang X; Wang Y
    Cell; 2019 Jan; 176(1-2):239-253.e16. PubMed ID: 30503210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
    Ganguly C; Rostami S; Long K; Aribam SD; Rajan R
    J Biol Chem; 2024 Jun; 300(6):107295. PubMed ID: 38641067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
    Meeske AJ; Marraffini LA
    Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
    Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
    RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-time observation of DNA target interrogation and product release by the RNA-guided endonuclease CRISPR Cpf1 (Cas12a).
    Singh D; Mallon J; Poddar A; Wang Y; Tippana R; Yang O; Bailey S; Ha T
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5444-5449. PubMed ID: 29735714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis ofCas6b processing and CRISPR RNA stability.
    Richter H; Lange SJ; Backofen R; Randau L
    RNA Biol; 2013 May; 10(5):700-7. PubMed ID: 23392318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for promiscuous PAM recognition in type I-E Cascade from E. coli.
    Hayes RP; Xiao Y; Ding F; van Erp PB; Rajashankar K; Bailey S; Wiedenheft B; Ke A
    Nature; 2016 Feb; 530(7591):499-503. PubMed ID: 26863189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR RNA and anti-CRISPR protein binding to the
    Hong S; Ka D; Yoon SJ; Suh N; Jeong M; Suh JY; Bae E
    J Biol Chem; 2018 Feb; 293(8):2744-2754. PubMed ID: 29348170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA targeting by the type III-A CRISPR-Cas Csm complex of Thermus thermophilus.
    Staals RH; Zhu Y; Taylor DW; Kornfeld JE; Sharma K; Barendregt A; Koehorst JJ; Vlot M; Neupane N; Varossieau K; Sakamoto K; Suzuki T; Dohmae N; Yokoyama S; Schaap PJ; Urlaub H; Heck AJ; Nogales E; Doudna JA; Shinkai A; van der Oost J
    Mol Cell; 2014 Nov; 56(4):518-30. PubMed ID: 25457165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Reconstitution and Crystallization of Cas9 Endonuclease Bound to a Guide RNA and a DNA Target.
    Anders C; Niewoehner O; Jinek M
    Methods Enzymol; 2015; 558():515-537. PubMed ID: 26068752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis of stringent PAM recognition by CRISPR-C2c1 in complex with sgRNA.
    Wu D; Guan X; Zhu Y; Ren K; Huang Z
    Cell Res; 2017 May; 27(5):705-708. PubMed ID: 28374750
    [No Abstract]   [Full Text] [Related]  

  • 37. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.
    Wang B; Zhang T; Yin J; Yu Y; Xu W; Ding J; Patel DJ; Yang H
    Mol Cell; 2021 Mar; 81(5):1100-1115.e5. PubMed ID: 33472057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A scoutRNA Is Required for Some Type V CRISPR-Cas Systems.
    Harrington LB; Ma E; Chen JS; Witte IP; Gertz D; Paez-Espino D; Al-Shayeb B; Kyrpides NC; Burstein D; Banfield JF; Doudna JA
    Mol Cell; 2020 Aug; 79(3):416-424.e5. PubMed ID: 32645367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cmr4 is the slicer in the RNA-targeting Cmr CRISPR complex.
    Zhu X; Ye K
    Nucleic Acids Res; 2015 Jan; 43(2):1257-67. PubMed ID: 25541196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.